

## REGENX BIOSCIENCES LICENSES KEY INTELLECTUAL PROPERTY FROM UNIVERSITY OF PENNSYLVANIA

### *Acquires Worldwide, Exclusive Rights to Novel AAV Vectors for Commercial Therapeutics and Research*

WASHINGTON -- ReGenX Biosciences, LLC announced that it has completed license agreements to secure the exclusive rights to key intellectual property covering novel recombinant adeno-associated viral (rAAV) vectors discovered at the University of Pennsylvania in the laboratory of James M. Wilson, M.D., Ph.D. The technology platform exclusively licensed by ReGenX is based on discoveries by Dr. Wilson that led to the identification of over 100 new adeno-associated viruses.

ReGenX, a privately held biopharmaceutical company, was formed to develop and commercialize therapeutics and life science research products utilizing **NAV**<sup>TM</sup> – a gene delivery technology that includes proprietary rAAV vectors that offer a platform for safer, highly efficient and specific gene delivery. ReGenX holds the exclusive, research, development and commercial rights for a range of novel vectors including rAAV7, rAAV8, rAAV9, and rAAVrh.10. The **NAV** technology includes a portfolio of nearly 40 issued patents and 50 pending patent applications on a wide range of biologic and genetic material delivery and therapeutic target patents.

“By acquiring the exclusive rights to novel recombinant AAV vectors such as rAAV7, rAAV8, rAAV9, rAAVrh.10 and others, ReGenX is in a strong position to enable and advance the development of novel gene-based medicines. The cumulative research and development to date from which ReGenX derives its capabilities is well-positioned to have an immediate and substantive impact on the translation of research into clinically meaningful therapies,” said Kenneth T. Mills, President and Chief Executive Officer of ReGenX. “We believe that a great need exists for highly efficient delivery of genetic material and that our **NAV** technology will become one of the cornerstones for the biotechnology industry.”

ReGenX BioSciences was formed with the University of Pennsylvania, GlaxoSmithKline and FO XKISER. In addition to significant intellectual property that was licensed directly from the University of Pennsylvania, ReGenX also received certain rights in the **NAV** technology through an exclusive agreement with GlaxoSmithKline, which supplied research funding to Dr. Wilson’s lab that yielded many of the discoveries of the novel rAAV vectors. FO XKISER provided the initial funding for ReGenX.

“The discovery and development of this platform could not have been possible without the intellect, talent and drive that has embodied Dr. Wilson and his lab,” said Mr. Mills, “ReGenX is pleased to have the support of FO XKISER, GlaxoSmithKline and the University of Pennsylvania in establishing a company that can focus on enabling the broad development of such an important platform technology.”

### **About ReGenX BioSciences**

ReGenX BioSciences is leading the effort to translate promising gene delivery applications into a pipeline of next generation personalized therapies for a range of severe diseases with serious unmet needs. We believe that the **NAV**<sup>TM</sup> technology to which we have exclusive rights represents the potential promise of curing the root cause of disease rather than the symptoms, and we are committed to establishing

best in class standards for our **NAV** vectors. Our intent is to develop treatments for a number of rare, genetic diseases including hypercholesterolemia, mucopolysaccharidosis, and retinitis pigmentosa and ensure continuing access for our **NAV** technology through innovative partnerships, license opportunities and the expansion of our growing team of global collaborators. ReGenX holds exclusive rights to a portfolio of over 90 patents and patent applications pertaining to its NAV technology and related applications.